- Male or female, age 21 to 70 years old.
- Patient undergoing with anti-neoplastic agent(s) known to have genotoxic activity
(e.g., cyclophosphamide, 5-FU, cisplatin, Ara-C.
- X-irradiation may be considered, so long as a substantial fraction of red marrow is
exposed (e.g., femur or chest/trunk region);
- treatment could be ongoing therapy or initial therapy.
Type of Study:
Observational Model: Defined Population, Time Perspective: Longitudinal, Time Perspective: Prospective
Yuhchyau Chen, MD, Ph.D
Universtiy of Rochester, Dept of Radiation Oncology
United States: Institutional Review Board
|University of Rochester||Rochester, New York 14642|